Literature DB >> 12952285

Thymic function and output of recent thymic emigrant T cells during intracranial glioma progression.

Robert M Prins1, Martin R Graf, Randall E Merchant, Keith L Black, Christopher J Wheeler.   

Abstract

One of the hallmarks of patients with glioblastoma multiforme (GBM) is profound lymphopenia mostly confined to the T cell lineage. A deficiency in the production of naive T cells from the thymus could contribute to the lymphopenia seen in GBM patients. In this study we asked whether thymic function and the production of recent thymic emigrant (RTE) T cells from the thymus was influenced by intracranial (i.c.) glioma progression. We found significant thymic involution in animals with progressive i.c. gliomas. Involuted thymi from animals with progressive i.c. T9.F gliomas showed dramatic losses of CD4+ CD8+ (DP) thymocytes. Microscopic analysis complemented those findings by demonstrating a reversal of the typical cortico-medullary structure. Significant increases in apoptosis accompanied the rapid loss of viable thymocytes, which was prevented in part by adrenalectomy, suggesting a dominant role for endogenous glucocorticoids. This thymic involution was also associated with a significant decrease in peripheral RTE T cells, reflecting the diminished thymic function. Finally, we found that CD8+ RTE T cells were enriched in progressively growing T9 gliomas, which points to an immunological role for RTE's in anti-glioma immunity. Our findings may shed light on the significance of thymic function for anti-glioma immunity and the response to immunotherapeutic treatment paradigms.

Entities:  

Mesh:

Year:  2003        PMID: 12952285     DOI: 10.1007/BF02700019

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  35 in total

Review 1.  Tumor immunology: the glass is half full.

Authors:  J A Sogn
Journal:  Immunity       Date:  1998-12       Impact factor: 31.745

2.  Restraint stress-induced thymic involution and cell apoptosis are dependent on endogenous glucocorticoids.

Authors:  N Tarcic; H Ovadia; D W Weiss; J Weidenfeld
Journal:  J Neuroimmunol       Date:  1998-02       Impact factor: 3.478

3.  Apoptotic elimination of peripheral T lymphocytes in patients with primary intracranial tumors.

Authors:  L A Morford; A R Dix; W H Brooks; T L Roszman
Journal:  J Neurosurg       Date:  1999-12       Impact factor: 5.115

4.  The brain parenchyma is permissive for full antitumor CTL effector function, even in the absence of CD4 T cells.

Authors:  P R Walker; T Calzascia; V Schnuriger; N Scamuffa; P Saas; N de Tribolet; P Y Dietrich
Journal:  J Immunol       Date:  2000-09-15       Impact factor: 5.422

5.  Quantitation of T-cell neogenesis in vivo after allogeneic bone marrow transplantation in adults.

Authors:  E P Hochberg; A C Chillemi; C J Wu; D Neuberg; C Canning; K Hartman; E P Alyea; R J Soiffer; S A Kalams; J Ritz
Journal:  Blood       Date:  2001-08-15       Impact factor: 22.113

Review 6.  Immune defects observed in patients with primary malignant brain tumors.

Authors:  A R Dix; W H Brooks; T L Roszman; L A Morford
Journal:  J Neuroimmunol       Date:  1999-12       Impact factor: 3.478

Review 7.  T cell precursors in man and mice.

Authors:  B Blom; P C Res; H Spits
Journal:  Crit Rev Immunol       Date:  1998       Impact factor: 2.214

8.  Changes in thymic function with age and during the treatment of HIV infection.

Authors:  D C Douek; R D McFarland; P H Keiser; E A Gage; J M Massey; B F Haynes; M A Polis; A T Haase; M B Feinberg; J L Sullivan; B D Jamieson; J A Zack; L J Picker; R A Koup
Journal:  Nature       Date:  1998-12-17       Impact factor: 49.962

9.  Immunobiology of primary intracranial tumours. II. Analysis of lymphocyte subpopulations in patients with primary brain tumours.

Authors:  W H Brooks; T L Roszman; M S Mahaley; R E Woosley
Journal:  Clin Exp Immunol       Date:  1977-07       Impact factor: 4.330

10.  In vitro analysis of the proliferative potential of T cells from patients with brain tumor: glioma-associated immunosuppression unrelated to intrinsic cellular defect.

Authors:  D W McVicar; D F Davis; R E Merchant
Journal:  J Neurosurg       Date:  1992-02       Impact factor: 5.115

View more
  12 in total

1.  Anti-GITR therapy promotes immunity against malignant glioma in a murine model.

Authors:  Jason Miska; Aida Rashidi; Alan L Chang; Megan E Muroski; Yu Han; Lingjiao Zhang; Maciej S Lesniak
Journal:  Cancer Immunol Immunother       Date:  2016-10-12       Impact factor: 6.968

Review 2.  T-cell Dysfunction in Glioblastoma: Applying a New Framework.

Authors:  Karolina I Woroniecka; Kristen E Rhodin; Pakawat Chongsathidkiet; Kristin A Keith; Peter E Fecci
Journal:  Clin Cancer Res       Date:  2018-03-28       Impact factor: 12.531

3.  Comparative analysis of thymic subpopulations during different modes of atrophy identifies the reactive oxygen species scavenger, N-acetyl cysteine, to increase the survival of thymocytes during infection-induced and lipopolysaccharide-induced thymic atrophy.

Authors:  Shamik Majumdar; Vasista Adiga; Abinaya Raghavan; Supriya Rajendra Rananaware; Dipankar Nandi
Journal:  Immunology       Date:  2019-02-11       Impact factor: 7.397

Review 4.  An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma.

Authors:  David A Reardon; Kai W Wucherpfennig; Gordon Freeman; Catherine J Wu; E Antonio Chiocca; Patrick Y Wen; William T Curry; Duane A Mitchell; Peter E Fecci; John H Sampson; Glenn Dranoff
Journal:  Expert Rev Vaccines       Date:  2013-06       Impact factor: 5.217

Review 5.  Brain tumor immunotherapy: an immunologist's perspective.

Authors:  Lois A Lampson
Journal:  J Neurooncol       Date:  2003 Aug-Sep       Impact factor: 4.130

6.  Thymus-derived rather than tumor-induced regulatory T cells predominate in brain tumors.

Authors:  Derek A Wainwright; Sadhak Sengupta; Yu Han; Maciej S Lesniak
Journal:  Neuro Oncol       Date:  2011-09-08       Impact factor: 12.300

Review 7.  T cell dysfunction in glioblastoma: a barrier and an opportunity for the development of successful immunotherapies.

Authors:  Josephina A Jansen; Antonio Omuro; Liliana E Lucca
Journal:  Curr Opin Neurol       Date:  2021-12-01       Impact factor: 5.710

8.  Association of neutrophil-lymphocyte ratio and T lymphocytes with the pathogenesis and progression of HBV-associated primary liver cancer.

Authors:  Xiaoli Liu; Lingling He; Junyan Han; Lijia Wang; Mengge Li; Yuyong Jiang; Xianbo Wang; Zhiyun Yang
Journal:  PLoS One       Date:  2017-02-23       Impact factor: 3.240

Review 9.  Thymic Function Associated With Cancer Development, Relapse, and Antitumor Immunity - A Mini-Review.

Authors:  Weikan Wang; Rachel Thomas; Olga Sizova; Dong-Ming Su
Journal:  Front Immunol       Date:  2020-04-30       Impact factor: 7.561

10.  A novel mechanism of tumor-induced thymic atrophy in mice bearing H22 hepatocellular carcinoma.

Authors:  Sujun Sun; Haiyu Ji; Yingying Feng; Yu Kang; Juan Yu; Anjun Liu
Journal:  Cancer Manag Res       Date:  2018-03-05       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.